Autoimmune pancreatitis

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose of review. Autoimmune pancreatitis (ALP) is an increasingly recognized clinical condition. Our objective is to provide a concise review of the advances in the past year in our understanding of AlP. Recent findings. In a hospital survey from Japan, the prevalence of AlP was estimated at 0.82 per 100 000 individuals. The pathogenesis of AlP remains unclear but a recent report noted that T helper type 2 and T regulatory cells predominantly mediate the immune reaction in AlP. Genetic associations that may predispose to relapse of AIP were reported. Multiple case series further described the clinical profile of AlP and its extrapancreatic manifestations. A large series on immunoglobulin G4 (IgG4)-associated cholangitis noted that patients with IgG4-associated cholangitis presented with obstructive jaundice and had increased serum IgG4 levels and IgG4-positive cells in bile duct biopsy specimens. Tissue IgG4 staining is likely to be a useful adjunct to serological diagnosis. AIP is steroid-responsive but maintaining remission continues to remain challenging. Presently Iow-dose steroids or immunomodulators are being used but efficacy of these medications remains to be determined. Summary. There has been significant progress in understanding the clinical profile of AIP but knowledge of pathogenesis remains limited. Treatment practices vary widely and management of refractory disease continues to be challenging.

Original languageEnglish (US)
Pages (from-to)591-596
Number of pages6
JournalCurrent Opinion in Gastroenterology
Volume24
Issue number5
DOIs
StatePublished - Sep 2008

Fingerprint

Pancreatitis
Immunoglobulins
Cholangitis
Steroids
Th2 Cells
Obstructive Jaundice
Immunologic Factors
Disease Management
Bile Ducts
Japan
Staining and Labeling
Biopsy
Recurrence
Serum
Therapeutics

Keywords

  • Autoimmune pancreatitis
  • Immunoglobulin G4
  • Immunoglobulin G4-associated systemic disease
  • Pancreatic mass

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Autoimmune pancreatitis. / Pannala, Rahul; Chari, Suresh T.

In: Current Opinion in Gastroenterology, Vol. 24, No. 5, 09.2008, p. 591-596.

Research output: Contribution to journalArticle

@article{1a416ace34774edbb77dc262e3d1097f,
title = "Autoimmune pancreatitis",
abstract = "Purpose of review. Autoimmune pancreatitis (ALP) is an increasingly recognized clinical condition. Our objective is to provide a concise review of the advances in the past year in our understanding of AlP. Recent findings. In a hospital survey from Japan, the prevalence of AlP was estimated at 0.82 per 100 000 individuals. The pathogenesis of AlP remains unclear but a recent report noted that T helper type 2 and T regulatory cells predominantly mediate the immune reaction in AlP. Genetic associations that may predispose to relapse of AIP were reported. Multiple case series further described the clinical profile of AlP and its extrapancreatic manifestations. A large series on immunoglobulin G4 (IgG4)-associated cholangitis noted that patients with IgG4-associated cholangitis presented with obstructive jaundice and had increased serum IgG4 levels and IgG4-positive cells in bile duct biopsy specimens. Tissue IgG4 staining is likely to be a useful adjunct to serological diagnosis. AIP is steroid-responsive but maintaining remission continues to remain challenging. Presently Iow-dose steroids or immunomodulators are being used but efficacy of these medications remains to be determined. Summary. There has been significant progress in understanding the clinical profile of AIP but knowledge of pathogenesis remains limited. Treatment practices vary widely and management of refractory disease continues to be challenging.",
keywords = "Autoimmune pancreatitis, Immunoglobulin G4, Immunoglobulin G4-associated systemic disease, Pancreatic mass",
author = "Rahul Pannala and Chari, {Suresh T}",
year = "2008",
month = "9",
doi = "10.1097/MOG.0b013e32830b10d2",
language = "English (US)",
volume = "24",
pages = "591--596",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Autoimmune pancreatitis

AU - Pannala, Rahul

AU - Chari, Suresh T

PY - 2008/9

Y1 - 2008/9

N2 - Purpose of review. Autoimmune pancreatitis (ALP) is an increasingly recognized clinical condition. Our objective is to provide a concise review of the advances in the past year in our understanding of AlP. Recent findings. In a hospital survey from Japan, the prevalence of AlP was estimated at 0.82 per 100 000 individuals. The pathogenesis of AlP remains unclear but a recent report noted that T helper type 2 and T regulatory cells predominantly mediate the immune reaction in AlP. Genetic associations that may predispose to relapse of AIP were reported. Multiple case series further described the clinical profile of AlP and its extrapancreatic manifestations. A large series on immunoglobulin G4 (IgG4)-associated cholangitis noted that patients with IgG4-associated cholangitis presented with obstructive jaundice and had increased serum IgG4 levels and IgG4-positive cells in bile duct biopsy specimens. Tissue IgG4 staining is likely to be a useful adjunct to serological diagnosis. AIP is steroid-responsive but maintaining remission continues to remain challenging. Presently Iow-dose steroids or immunomodulators are being used but efficacy of these medications remains to be determined. Summary. There has been significant progress in understanding the clinical profile of AIP but knowledge of pathogenesis remains limited. Treatment practices vary widely and management of refractory disease continues to be challenging.

AB - Purpose of review. Autoimmune pancreatitis (ALP) is an increasingly recognized clinical condition. Our objective is to provide a concise review of the advances in the past year in our understanding of AlP. Recent findings. In a hospital survey from Japan, the prevalence of AlP was estimated at 0.82 per 100 000 individuals. The pathogenesis of AlP remains unclear but a recent report noted that T helper type 2 and T regulatory cells predominantly mediate the immune reaction in AlP. Genetic associations that may predispose to relapse of AIP were reported. Multiple case series further described the clinical profile of AlP and its extrapancreatic manifestations. A large series on immunoglobulin G4 (IgG4)-associated cholangitis noted that patients with IgG4-associated cholangitis presented with obstructive jaundice and had increased serum IgG4 levels and IgG4-positive cells in bile duct biopsy specimens. Tissue IgG4 staining is likely to be a useful adjunct to serological diagnosis. AIP is steroid-responsive but maintaining remission continues to remain challenging. Presently Iow-dose steroids or immunomodulators are being used but efficacy of these medications remains to be determined. Summary. There has been significant progress in understanding the clinical profile of AIP but knowledge of pathogenesis remains limited. Treatment practices vary widely and management of refractory disease continues to be challenging.

KW - Autoimmune pancreatitis

KW - Immunoglobulin G4

KW - Immunoglobulin G4-associated systemic disease

KW - Pancreatic mass

UR - http://www.scopus.com/inward/record.url?scp=55549114030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549114030&partnerID=8YFLogxK

U2 - 10.1097/MOG.0b013e32830b10d2

DO - 10.1097/MOG.0b013e32830b10d2

M3 - Article

VL - 24

SP - 591

EP - 596

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 5

ER -